AngioDynamics (NASDAQ:ANGO) Stock Rating Upgraded by Zacks Research

AngioDynamics (NASDAQ:ANGO) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday, Zacks reports.

Several other research analysts have also recently weighed in on ANGO. Canaccord Genuity Group raised their target price on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Finally, HC Wainwright increased their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, AngioDynamics currently has an average rating of “Moderate Buy” and an average target price of $19.50.

AngioDynamics Trading Down 7.2%

AngioDynamics stock opened at $14.42 on Monday. The company’s 50-day moving average price is $15.47 and its two-hundred day moving average price is $13.08. The stock has a market cap of $606.36 million, a price-to-earnings ratio of -16.57 and a beta of 0.30. AngioDynamics has a 52 week low of $9.39 and a 52 week high of $16.29.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The business had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Research analysts expect that AngioDynamics will post -0.25 earnings per share for the current fiscal year.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On AngioDynamics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC acquired a new stake in AngioDynamics in the 2nd quarter worth approximately $38,000. Legal & General Group Plc acquired a new position in AngioDynamics during the second quarter valued at approximately $45,000. Public Employees Retirement System of Ohio acquired a new position in AngioDynamics during the second quarter valued at approximately $64,000. Arrowstreet Capital Limited Partnership raised its position in shares of AngioDynamics by 0.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier’s stock valued at $8,624,000 after purchasing an additional 5,509 shares during the period. Finally, State of Wyoming acquired a new stake in shares of AngioDynamics in the second quarter worth $72,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.